Addition of maintenance olaparib slows advanced ovarian cancer
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...
Dec 19, 2019
0
0